Author Archives: Natalie Themm
The “White Glove” Delivery: How a Joke Landed Me in Iceland
The “White Glove” Delivery: How a Joke Landed Me in Iceland
Owlet Dream Duo™ 3 Named ‘Best for Monitoring Baby’s Health’ in PARENTS 2026 Best for Baby Awards
The Only Pediatric Health Platform Pairing an FDA-Cleared Infant Wearable with a Cybersecurity-Certified Video Monitor Earns Top Recognition from Editors and Expert Testers
Kimbell & Associates: Highlights of President Trump’s FY 2027 Budget Request
Kimbell & Associates offers highlights of President Trump’s FY 2027 Budget Request
Fluidx Medical Announces First Patient Treated with Novel Embolic Gel
Gel embolic device designed to simplify the embolization procedure and reduce risks to the patient.
BioUtah CEO, Kelvyn Cullimore, Makes the Rounds in DC
BioUtah CEO, Kelvyn Cullimore, Makes the Rounds in DC
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
First new FDA-approved treatment option in nearly 20 years for families living with this rare lysosomal storage disease.
BIOUTAH JOINED NATIONAL CONVENING ON AMERICA’S BIOTECH MOMENT
Biotech is playing an increasingly important role in U.S. economic competitiveness and national security, and Utah plays a key role in contributing to the strength of the American biotech ecosystem.
Kolosis BIO® Expands Surgical Biologics Portfolio with Launch of APEXecm™
The addition of APEXecm reflects Kolosis’s continued commitment to developing and commercializing best-in-class solutions for the surgical community
Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer
Approval reinforces Myriad’s leadership in comprehensive HRD testing and establishes MyChoice CDx as the only FDA-approved companion diagnostic for Zejula in the U.S.
Merit Medical Launches the Resilience Through-the-Scope Esophageal Stent
New Resilience™ deployment system, anti-migration stent design, and unique stent sizes offer physicians control while enhancing treatment for patients with esophageal fistulas and malignant strictures
Glafabra Therapeutics Receives FDA Orphan Drug Designation for GT-GLA-S03, Advancing a Redosable Cell Therapy for Fabry Disease
For Fabry patients, a potential path to converting 130 clinic visits into one treatment every five years.
BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
New results demonstrate early VOXZOGO treatment leads to durable and sustained improvements in skeletal growth-related health outcomes, including proportionality, arm span and body mass index, building on over 10,000 patient-years of data
